ALXN2420, a 16-amino-acid peptide growth hormone receptor antagonist, was well tolerated up to 120 mg/day and reduced serum IGF-1 by up to approximately 50% in a first-in-human Phase 1 study of 101 healthy subjects published in the European Journal of Endocrinology. Pharmacokinetics were…
# ALXN2420 Phase 1: GH receptor peptide antagonist lowers IGF-1
ALXN2420 , a 16-amino-acid peptide antagonist of the growth hormone receptor , was well tolerated at subcutaneous doses up to 120 mg/day and reduced serum IGF-1 by up to approximately 50% in a first-in-human Phase 1 study in healthy subjects. The results, published in the European Journal of Endocrinology , come from a randomized, double-blind, placebo-controlled trial that enrolled 101 eligible and evaluable healthy subjects at a single centre.
The study is the first clinical report on ALXN2420, and it answers the questions a first-in-human trial is built to answer: whether the peptide is safe, how it is absorbed and cleared, and whether it hits its biological target. Pharmacokinetics were dose-proportional, with a terminal half-life of approximately 22 hours. Dose-related decreases in serum IGF-1 appeared at doses of 20 mg and above, and higher single doses produced suppression that lasted up to 72 hours.
ALXN2420 is being developed as a combination therapy for patients with acromegaly who are inadequately controlled on somatostatin receptor ligands . The study authors concluded that doses up to 120 mg/day appeared safe and substantially decreased IGF-1 in healthy subjects, and that the data support further testing in patients. The trial did not enroll patients with acromegaly, so the efficacy question remains open, but the size and consistency of the pharmacodynamic effect provide the warrant for moving the peptide into that population.
The single ascending dose phase and the two-week multiple ascending dose phase produced a coherent pharmacokinetic profile. ALXN2420 exposure increased in proportion to dose, and the approximately 22-hour terminal half-life is compatible with once-daily subcutaneous dosing. No dose-limiting toxicity emerged, and the highest dose tested, 120 mg/day, was described as well tolerated, with no safety concerns.
The pharmacodynamic results are the more consequential part of the report. Serum IGF-1 began to fall at ALXN2420 doses of 20 mg or more, and the effect scaled with dose. At doses of 40 mg or higher, the maximal mean change from baseline versus placebo was approximately 20-30% after single ascending doses. After two weeks of repeated daily dosing, the same dose range produced a maximal mean change of approximately 40-50% from baseline versus placebo.
That gap between single-dose and repeated-dose effects is the key finding for trial design. Two weeks of daily administration suggested a cumulative effect compared with a single dose, meaning the pharmacodynamic action builds beyond the first few days of treatment. Higher doses also produced more prolonged IGF-1 reductions, up to 72 hours after single doses and persisting through the end of treatment in the multiple ascending dose period.
The trial was a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and two-week multiple ascending dose study at a single centre. Healthy subjects received subcutaneous injections of ALXN2420 or placebo. The primary endpoint was safety and tolerability; pharmacokinetic parameters were measured, and serum IGF-1 was tracked as a pharmacodynamic endpoint. Enrollment reached 101 eligible and evaluable healthy subjects.
The healthy-subject design is the right instrument for first-in-human questions. Because volunteers are not taking concomitant medications for a chronic disease, the pharmacokinetic data are clean, and IGF-1 responses can be attributed to the drug rather than to disease fluctuation. The single-centre setting also allows standardized sampling schedules and tight control of dosing conditions, which matters when measuring a biomarker with natural variation over the day.
The design has clear limits, and they should be stated plainly. It cannot demonstrate efficacy in acromegaly, because the subjects did not have the disease. IGF-1 is a surrogate measure; the trial did not assess tumor control, symptom burden, or long-term morbidity. Two weeks of repeat dosing cannot reveal late toxicities, injection-site reactions from chronic use, or immunogenicity that develops over months. What the design can establish is tolerability at the intended dose range and a proof-of-mechanism signal. That is what it did.
Acromegaly is a rare disease, typically caused by a growth hormone-secreting pituitary adenoma. Excess growth hormone drives the liver and other tissues to produce IGF-1, and IGF-1 is the mediator of many of the clinical features of the disease. It is also the standard biochemical marker used to monitor disease control, because growth hormone itself is secreted in pulses and has a very short half-life, while IGF-1 circulates long enough to give a stable readout.
Growth hormone acts through the growth hormone receptor, a class I cytokine receptor that dimerizes when the hormone binds. Receptor activation recruits JAK2 and STAT5, and the resulting signaling cascade drives IGF-1 gene expression, mainly in the liver. A receptor antagonist works upstream of IGF-1 production: by occupying the receptor and preventing normal signaling, it suppresses the downstream output that drives the disease.
ALXN2420's 16-amino-acid structure distinguishes it from the older GH receptor blocker pegvisomant, which is a large, PEGylated protein. A small synthetic peptide can be produced by solid-phase synthesis and is a distinct chemical entity with its own pharmacology. The observed kinetics make biological sense: the peptide's terminal half-life is approximately 22 hours, but IGF-1 itself turns over slowly, which explains why a single dose can suppress circulating IGF-1 for 72 hours. The cumulative effect seen with repeated dosing suggests that the full pharmacodynamic effect develops over days, an important input for dosing decisions in later trials.
The clinical rationale for a receptor antagonist in acromegaly rests on the limits of current medical therapy. Somatostatin receptor ligand monotherapy does not optimally control circulating IGF-1 in all patients, and receptor-level blockade acts through a different mechanism than the pituitary-targeting somatostatin drugs. That is why ALXN2420 is positioned as an add-on for patients who remain inadequately controlled on somatostatin receptor ligands.
Peptide Atlas's internal reference page for growth hormone, which serves as the repository entry for the peptide itself, currently holds 0 registered clinical trials on file and 10 third-party lab purity tests, with the highest observed purity at 98.083%. The reference URL is https://peptideatlas.co/peptides/growth-hormone.
The zero trial count on that page should not be misread as an absence of clinical history for growth hormone in general; recombinant growth hormone has decades of clinical use. It reflects the distinction between a peptide reference entry and a drug development program. The ALXN2420 study, by contrast, is an interventional trial with a defined population, endpoints, and regulatory path, and it now sits in the formal clinical record.
The 10 third-party purity tests and the 98.083% highest observed purity figure on file are the more instructive data point for the peptide field. Reference peptides used in research and development are subject to external analytical verification, because subtle differences in purity can change receptor binding and bioactivity. As ALXN2420 moves toward later-stage trials, the same kind of third-party testing infrastructure will be the verification layer for clinical-grade material.
For researchers designing the next studies, the cumulative pharmacodynamic effect is the single most useful number in this report. Dose selection cannot be based on single-dose data alone; the observation that two weeks of daily dosing roughly doubled the maximal mean IGF-1 reduction at doses of 40 mg or higher means that later trials will need pharmacokinetic-pharmacodynamic modeling that accounts for this build-up. The 20 mg threshold for a measurable effect and the 40 mg and higher range for maximal effects bracket the dose-finding window for Phase 2.
For clinicians, the relevance is conditional but concrete. If the peptide performs in patients as it did in healthy subjects, it would be a daily subcutaneous addition to somatostatin receptor ligand therapy in patients who are not controlled on that therapy alone. The approximately 22-hour half-life supports once-daily dosing, and IGF-1 is an established monitoring biomarker that would allow dose titration in the clinic. But the study offers no evidence yet on symptoms, tumor volume, or metabolic effects, and those outcomes will determine the drug's actual clinical value.
For the peptide supply chain, the implications are operational. A 16-amino-acid peptide at daily doses up to 120 mg represents a substantial active pharmaceutical ingredient requirement per patient per year, and clinical progression will demand GMP synthesis at scale, formulation for subcutaneous injection, and release testing for purity and stability. The analytical standards captured in peptide reference repositories, where records such as the growth hormone purity tests on file live, are the benchmarks against which clinical-grade batches will be judged.
The caveats are part of the record. This is a single-centre Phase 1 study in healthy subjects, not in patients with acromegaly. Repeated dosing was limited to two weeks, so longer-term safety and efficacy were not assessed. The trial did not test ALXN2420 in combination with somatostatin receptor ligands, which is the intended clinical use. And IGF-1 suppression is a biomarker, not a demonstration of disease control.
Three questions follow directly. First, how will ALXN2420 perform in patients with acromegaly when added to somatostatin receptor ligand therapy, including patients who are poor responders to that therapy? Second, what dosing regimen will be selected for longer-term trials, given the cumulative pharmacodynamic effect observed over the two-week multiple ascending dose phase? Third, will the safety and IGF-1 suppression profile be maintained with chronic dosing beyond two weeks, particularly with regard to injection-site tolerability, immunogenicity, and metabolic effects such as glucose handling?
Each of these questions has a settlement path. A Phase 2 add-on study in patients with acromegaly on stable somatostatin receptor ligand doses, treated for several months, with IGF-1 normalization as a central endpoint, would answer the efficacy question and begin to answer the chronic safety question. Formal pharmacokinetic-pharmacodynamic modeling of the cumulative effect would answer the dosing question before that study is designed. What the present study establishes is narrower but real: a 16-amino-acid growth hormone receptor antagonist that is safe at 120 mg/day, has predictable kinetics, and lowers IGF-1 by up to roughly half in healthy subjects. That is the foundation the next trial will build on.
Peptides referenced: Growth Hormone, IGF-1, Somatostatin.
Related reading: Peptide Nanostructures Kill Resistant Bacteria and Restore Meropenem, GLP-1 Analogs for Psoriatic Arthritis With Obesity and Diabetes, NCI tests neoantigen vaccine in metastatic triple-negative breast cancer, Tirzepatide tied to lower predicted 10-year CVD risk over 3 years.